Loading…
Natural Capsules (NATCAPSUQ)₹147.00+4.99%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Natural Capsules reported sales of ₹48.85 Cr, up 7.7% from Jun 2025, and net profit of −₹5.76 Cr. For the year to Mar 2026, sales were ₹188 Cr and net profit −₹25.05 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 37.59 | 40.10 | 40.33 | 39.27 | 41.34 | 43.90 | 45.05 | 45.35 | 45.91 | 37.86 | 58.63 | 48.85 |
| Expenses | 32.35 | 35.18 | 36.04 | 34.76 | 36.65 | 39.46 | 40.48 | 44.82 | 46.63 | 39.99 | 57.02 | 47.53 |
| Operating Profit | 5.11 | 4.71 | 4.10 | 4.36 | 4.49 | 4.26 | 4.38 | 0.31 | −0.88 | −2.31 | 1.32 | 1.11 |
| OPM % | 13.7% | 11.9% | 10.3% | 11.2% | 11.0% | 9.8% | 9.8% | 0.7% | −1.9% | −6.1% | 2.3% | 2.3% |
| Other Income | 0.36 | 0.51 | 0.93 | 0.19 | 0.12 | 0.12 | 0.31 | 0.37 | 0.17 | 0.46 | 0.77 | 2.36 |
| Interest | 1.15 | 1.23 | 1.39 | 1.48 | 1.64 | 1.53 | 1.63 | 2.52 | 2.67 | 2.84 | 2.88 | 4.95 |
| Depreciation | 2.16 | 2.18 | 2.19 | 2.27 | 2.34 | 2.32 | 2.15 | 4.20 | 4.28 | 4.35 | 4.27 | 4.32 |
| Profit before tax | 2.13 | 1.78 | 1.42 | 0.77 | 0.60 | 0.50 | 0.88 | −6.05 | −7.69 | −9.07 | −5.07 | −5.82 |
| Tax % | 27.1% | 33.0% | 32.2% | 21.9% | 201.7% | 78.5% | 41.6% | −8.1% | −9.1% | −21.7% | −2.0% | −1.5% |
| Net Profit | 1.57 | 1.22 | 0.98 | 0.61 | −0.62 | 0.12 | 0.53 | −5.59 | −7.01 | −7.14 | −4.99 | −5.76 |
| EPS (Rs) | 1.69 | 1.31 | 1.05 | 0.65 | −0.61 | 0.12 | 0.36 | −5.41 | −6.78 | −4.78 | −3.33 | −3.83 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 55.14 | 60.16 | 62.18 | 80.25 | 135 | 170 | 155 | 169 | 188 | 191 |
| Expenses | 48.88 | 54.94 | 55.87 | 67.86 | 110 | 135 | 135 | 151 | 188 | 191 |
| Operating Profit | 5.99 | 4.99 | 4.99 | 10.98 | 25.96 | 34.95 | 19.96 | 17.98 | −0.99 | −0.76 |
| OPM % | 10.0% | 8.1% | 9.0% | 14.1% | 19.0% | 21.1% | 13.1% | 10.1% | −0.5% | −0.4% |
| Other Income | 1.01 | 1.01 | 1.01 | 3.01 | 1.01 | 1.01 | 2.01 | 1.01 | 2.01 | 3.76 |
| Interest | 0.00 | 0.99 | 0.99 | 0.99 | 1.99 | 3.99 | 4.98 | 6.97 | 11.96 | 13.34 |
| Depreciation | 3.99 | 2.99 | 3.99 | 3.99 | 4.99 | 6.99 | 8.99 | 8.99 | 16.99 | 17.22 |
| Profit before tax | 2.01 | 1.99 | 0.99 | 8.99 | 18.98 | 24.98 | 7.99 | 2.99 | −27.96 | −27.65 |
| Tax % | 34.0% | 7.0% | 38.0% | 24.0% | 28.0% | 26.0% | 31.0% | 78.0% | −11.9% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 1.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 1.01 | 2.01 | 1.01 | 7.02 | 14.02 | 18.05 | 6.01 | 1.01 | −25.05 | −24.90 |
| EPS (Rs) | 1.20 | 2.07 | 0.93 | 7.44 | 14.99 | 20.07 | 5.96 | 0.43 | −16.48 | −18.72 |
| Dividend payout % | 56.1% | 32.0% | 43.0% | 9.0% | 5.0% | 5.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.98 | 5.99 | 5.98 | 5.98 | 6.98 | 8.97 | 8.97 | 9.96 | 9.97 |
| Reserves | 48.08 | 49.14 | 49.10 | 56.17 | 76.20 | 114 | 195 | 176 | 166 |
| Borrowings | 0.00 | 4.99 | 5.99 | 9.98 | 52.94 | 96.92 | 109 | 152 | 162 |
| Other Liabilities | 19.02 | 13.95 | 13.97 | 27.00 | 29.01 | 70.07 | 64.09 | 80.85 | 87.23 |
| Total Liabilities | 73.08 | 75.07 | 76.04 | 99.13 | 165 | 290 | 377 | 419 | 424 |
| Fixed Assets | 22.01 | 24.01 | 24.02 | 38.03 | 66.02 | 97.04 | 103 | 284 | 274 |
| CWIP | 1.01 | 2.01 | 2.01 | 7.02 | 20.05 | 88.16 | 144 | 0.00 | 4.01 |
| Investments | 4.99 | 4.99 | 5.99 | 0.00 | 0.00 | 0.00 | 2.99 | 2.99 | 2.99 |
| Other Assets | 45.07 | 43.06 | 45.02 | 54.08 | 79.06 | 105 | 127 | 133 | 143 |
| Inventories | 9.98 | 5.98 | 6.99 | 7.98 | 5.99 | 9.97 | 18.96 | 24.96 | 25.94 |
| Trade receivables | 31.01 | 32.03 | 30.03 | 27.02 | 26.03 | 52.03 | 54.03 | 62.03 | 70.99 |
| Cash & equivalents | 1.01 | 0.00 | 1.01 | 2.01 | 5.01 | 7.01 | 13.01 | 5.01 | 5.01 |
| Total Assets | 73.08 | 75.07 | 76.04 | 99.13 | 165 | 290 | 377 | 419 | 424 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 5.01 | 2.01 | 7.01 | 13.02 | −1.01 | 17.01 | −8.01 | 27.01 | 11.01 |
| Cash from investing activity | −0.99 | −6.99 | −5.98 | −15.97 | −45.93 | −105 | −72.86 | −43.88 | −10.98 |
| Cash from financing activity | −4.01 | 4.01 | −1.01 | 3.01 | 48.02 | 87.08 | 82.08 | 16.02 | −1.01 |
| Net cash flow | 0.00 | −0.99 | 0.00 | 0.00 | 0.99 | 0.00 | 0.99 | −1.99 | 0.00 |
| Capex | 1.04 | 7.10 | 5.29 | 23.44 | 45.99 | 106 | 71.47 | 44.58 | 11.52 |
| Free cash flow | 3.99 | −4.98 | 1.99 | −10.96 | −46.83 | −87.73 | −78.70 | −17.93 | −0.99 |
| CFO / OP % | 97.0% | 57.0% | 144.0% | 134.0% | 17.0% | 64.1% | −32.0% | 162.1% | −1,634.0% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 208 | 197 | 180 | 123 | 71 | 112 | 128 | 134 | 139 |
| Inventory days | 148 | 86 | 88 | 81 | 33 | 44 | 87 | 108 | 93 |
| Days payable | 185 | 114 | 91 | 159 | 98 | 127 | 141 | 166 | 197 |
| Cash conversion cycle | 173 | 171 | 180 | 46 | 8 | 31 | 76 | 79 | 37 |
| Working capital days | 186 | 143 | 121 | 35 | 73 | 61 | 80 | 53 | −1 |
| ROCE % | — | 5.0% | 4.0% | 11.1% | 21.0% | 15.0% | 5.0% | 3.0% | −5.0% |
For the Jun 2026 quarter, Natural Capsules reported sales of ₹48.85 Cr, up 7.7% year on year and net profit of −₹5.76 Cr. The operating margin was 2.3%.
Natural Capsules' sales for the year to Mar 2026 were ₹188 Cr; over the last twelve months they were ₹191 Cr.
Net profit for the year to Mar 2026 was −₹25.05 Cr, and −₹24.90 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−18.72.
Natural Capsules reported borrowings of ₹162 Cr at Mar 2026, against cash and equivalents of ₹5.01 Cr.
Cash from operations was ₹11.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.99 Cr.